Richard N. Kender serves as Independent Director of the Company. From October 1978 to September 2013, Mr. Kender held positions in a variety of corporate areas at Merck & Co., Inc. (“Merck”), a pharmaceutical company, most recently serving as Senior Vice President of Business Development and Corporate Licensing. Mr. Kender has served on the boards of directors of Poxel S.A. since 2015, Bicycle Therapeutics PLC since 2019, and ReViral Ltd since 2019. He previously served on the boards of directors of INC Research Holdings, Inc. between 2014 and 2017 and Abide Therapeutics, Inc. between 2015 and 2019. Mr. Kender received a B.S. in Accounting from Villanova University and an M.B.A. from Fairleigh Dickinson University.
As the Independent Director of Seres Therapeutics Inc, the total compensation of Richard Kender at Seres Therapeutics Inc is $88,152. There are 6 executives at Seres Therapeutics Inc getting paid more, with Eric Shaff having the highest compensation of $2,032,550.
Richard Kender is 64, he's been the Independent Director of Seres Therapeutics Inc since 2015. There are 4 older and 16 younger executives at Seres Therapeutics Inc. The oldest executive at Seres Therapeutics Inc is Dennis Ausiello, 74, who is the Independent Director.
Richard's mailing address filed with the SEC is C/O SERES THERAPEUTICS, INC., 101 CAMBRIDGE PARK DRIVE, CAMBRIDGE, MA, 02140.
Over the last 9 years, insiders at Seres Therapeutics Inc have traded over $37,132,594 worth of Seres Therapeutics Inc stock and bought 17,627,131 units worth $47,525,463 . The most active insiders traders include Noubar Afeyan, Health Ltp Fund General Par..., and Health Science Us Holdings,.... On average, Seres Therapeutics Inc executives and independent directors trade stock every 35 days with the average trade being worth of $251,393. The most recent stock trade was executed by Thomas Des Rosier on 15 August 2024, trading 2,656 units of MCRB stock currently worth $2,789.
seres therapeutics is a clinical stage biotherapeutic company focused on discovering and developing ecobiotic™ therapeutic products, novel drugs to treat important diseases by targeting the underlying biology of the human microbiome. founded by flagship venturelabs, seres is pioneering the first therapeutics that catalyze a shift to health by augmenting the biology of the microbiome. current candidates span infectious, metabolic, and inflammatory diseases. for more information, please visit http://serestherapeutics.com/.
Seres Therapeutics Inc executives and other stock owners filed with the SEC include: